Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors

Table 2 Comparison of liver function and portal venous pressure between the two groups before and after treatment (mean ± SD)

Group	ALT (U/L)		AST (U/L)		Portal venous pressure (cm H2O)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Research group (n = 50)	40.06 ± 6.15	71.45 ± 9.85a	53.16 ± 6.98	75.90 ± 10.09a	39.71 ± 7.56	28.93 ± 5.98a
Control group (n = 50)	40.99 ± 7.51	89.27 ± 11.26a	51.21 ± 9.32	95.45 ± 9.29a	39.83 ± 5.15	31.51 ± 5.88a
t value	0.676	8.425	1.184	10.076	0.089	2.174
P value	0.501	< 0.001	0.240	<0.001	0.929	0.032

^aP < 0.05 when compared to the same group prior to treatment.

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.